United States · Biotechnology startup
United States · Intellia Therapeutics
Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Funding reportedLast round: Post-IPO Debt
What company datasets say Intellia Therapeutics raised
Funding, as reported
Reported in all$400Min dollars
Last roundPost-IPO Debt
Investors listed5
SEC Form D$70M sold, 1 filing, last Sept 2015
Founders and team
From Intellia Therapeutics's own website and the SEC filings it signed: 8 on the team.
- Bill ChaseIndependent Director
- Brian GoffIndependent Director
- John LeonardExecutive Officer, Directori
- Jose RiveraExecutive Officeri
- Nessan BerminghamExecutive Officer, Directori
- Edward DulacTeam
- Maria NataleTeam
- Marika St. AmandTeam
On the board, as filediCarl GordonJean-Francois FormelaRachel Haurwitz
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Intellia Therapeutics in front of investors. Or tell us what we have wrong.